Which statement correctly distinguishes gepants from monoclonal antibodies in CGRP-targeted therapy?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which statement correctly distinguishes gepants from monoclonal antibodies in CGRP-targeted therapy?

Gepants and monoclonal antibodies inhibit the CGRP pathway in migraine, but they differ in form and administration. Gepants are oral small molecules that block the CGRP receptor, preventing CGRP signaling after you take them. Monoclonal antibodies against CGRP are large proteins given by injection and can target either the CGRP ligand or the CGRP receptor, resulting in long-lasting CGRP pathway inhibition with infrequent dosing. The statement that gepants are oral CGRP receptor antagonists is correct, and the statement that CGRP monoclonal antibodies (Umabs) are CGRP monoclonal antibodies is also correct. Therefore, both statements are true.

Gepants and monoclonal antibodies inhibit the CGRP pathway in migraine, but they differ in form and administration. Gepants are oral small molecules that block the CGRP receptor, preventing CGRP signaling after you take them. Monoclonal antibodies against CGRP are large proteins given by injection and can target either the CGRP ligand or the CGRP receptor, resulting in long-lasting CGRP pathway inhibition with infrequent dosing. The statement that gepants are oral CGRP receptor antagonists is correct, and the statement that CGRP monoclonal antibodies (Umabs) are CGRP monoclonal antibodies is also correct. Therefore, both statements are true.

More practice questions